Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 263

1.

Gastrointestinal stromal tumours.

Connolly EM, Gaffney E, Reynolds JV.

Br J Surg. 2003 Oct;90(10):1178-86. Review.

PMID:
14515284
2.

Imatinib mesylate: in the treatment of gastrointestinal stromal tumours.

Croom KF, Perry CM.

Drugs. 2003;63(5):513-22; discussion 523-4. Review.

PMID:
12600228
4.

Targeting c-kit mutations in solid tumors: scientific rationale and novel therapeutic options.

Demetri GD.

Semin Oncol. 2001 Oct;28(5 Suppl 17):19-26. Review.

PMID:
11740803
5.

Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor.

Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, Joensuu H, McGreevey LS, Chen CJ, Van den Abbeele AD, Druker BJ, Kiese B, Eisenberg B, Roberts PJ, Singer S, Fletcher CD, Silberman S, Dimitrijevic S, Fletcher JA.

J Clin Oncol. 2003 Dec 1;21(23):4342-9.

PMID:
14645423
6.

[Imatinib, a specific tyrosine-kinase inhibitor, for the treatment of patients with a gastrointestinal stroma cell tumor].

Gelderblom H, Hogendoorn PC, van der Graaf WT, Verweij J.

Ned Tijdschr Geneeskd. 2003 Oct 18;147(42):2051-5. Review. Dutch.

PMID:
14606351
8.

Gastrointestinal stromal tumors: rationale for surgical adjuvant trials with imatinib.

Cormier JN, Patel SR, Pisters PW.

Curr Oncol Rep. 2002 Nov;4(6):504-9. Review.

PMID:
12354363
9.

The role of KIT in the management of patients with gastrointestinal stromal tumors.

Hornick JL, Fletcher CD.

Hum Pathol. 2007 May;38(5):679-87. Review.

PMID:
17437861
10.

A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors.

Chen LL, Trent JC, Wu EF, Fuller GN, Ramdas L, Zhang W, Raymond AK, Prieto VG, Oyedeji CO, Hunt KK, Pollock RE, Feig BW, Hayes KJ, Choi H, Macapinlac HA, Hittelman W, Velasco MA, Patel S, Burgess MA, Benjamin RS, Frazier ML.

Cancer Res. 2004 Sep 1;64(17):5913-9.

11.

Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group.

Debiec-Rychter M, Dumez H, Judson I, Wasag B, Verweij J, Brown M, Dimitrijevic S, Sciot R, Stul M, Vranck H, Scurr M, Hagemeijer A, van Glabbeke M, van Oosterom AT; EORTC Soft Tissue and Bone Sarcoma Group.

Eur J Cancer. 2004 Mar;40(5):689-95.

PMID:
15010069
12.

Gastrointestinal stromal tumors: chemotherapy and imatinib.

Muler JH, Baker L, Zalupski MM.

Curr Oncol Rep. 2002 Nov;4(6):499-503. Review.

PMID:
12354362
13.

[Imatinib--a breakthrough in the treatment of gastrointestinal stromal tumors (GIST)].

Larsen JB.

Ugeskr Laeger. 2003 Sep 8;165(37):3503-7. Review. Danish.

PMID:
14531349
14.

Molecular research directions in the management of gastrointestinal stromal tumors.

Tarn C, Godwin AK.

Curr Treat Options Oncol. 2005 Nov;6(6):473-86. Review.

PMID:
16242052
15.

Surgical treatment of gastrointestinal stromal tumors in the imatinib (STI-571) era.

Wu PC, Langerman A, Ryan CW, Hart J, Swiger S, Posner MC.

Surgery. 2003 Oct;134(4):656-65; discussion 665-6.

PMID:
14605627
16.

Surgical resection of gastrointestinal stromal tumors after treatment with imatinib.

Andtbacka RH, Ng CS, Scaife CL, Cormier JN, Hunt KK, Pisters PW, Pollock RE, Benjamin RS, Burgess MA, Chen LL, Trent J, Patel SR, Raymond K, Feig BW.

Ann Surg Oncol. 2007 Jan;14(1):14-24.

PMID:
17072676
17.

Pathology and diagnostic criteria of gastrointestinal stromal tumors (GISTs): a review.

Miettinen M, Majidi M, Lasota J.

Eur J Cancer. 2002 Sep;38 Suppl 5:S39-51. Review.

PMID:
12528772
18.

Gastrointestinal stromal tumors: overview of pathologic features, molecular biology, and therapy with imatinib mesylate.

Koh JS, Trent J, Chen L, El-Naggar A, Hunt K, Pollock R, Zhang W.

Histol Histopathol. 2004 Apr;19(2):565-74. Review.

PMID:
15024716
19.

Gastrointestinal stromal tumors (GIST): a model for molecule-based diagnosis and treatment of solid tumors.

Kitamura Y, Hirota S, Nishida T.

Cancer Sci. 2003 Apr;94(4):315-20. Review. Erratum in: Cancer Sci. 2003 Oct;94(10):930.

20.

Gastrointestinal stromal tumours and their response to treatment with the tyrosine kinase inhibitor imatinib.

Mechtersheimer G, Egerer G, Hensel M, Rieker RJ, Libicher M, Lehnert T, Penzel R.

Virchows Arch. 2004 Feb;444(2):108-18. Epub 2004 Jan 20. Review.

PMID:
14735360
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk